Article in CPT: pharmacometrics & systems pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Abdullah HamadehSchool of Pharmacy, University of Waterloo, Kitchener, Ontario, Canada.ORCID 0000-0002-9419-1797
Ibrahim InceClinical Pharmacology, Boehringer Ingelheim Pharma GmbH & co. KG, Ingelheim am Rhein, Germany.ORCID 0000-0001-9036-7305
Kathleen M JobDivision of Clinical Pharmacology, Department of Pediatrics, School of Medicine, The University of Utah, Salt Lake City, Utah, USA.ORCID 0000-0003-0255-654X
Andreas KovarDMPK Modeling & Simulation, Sanofi R&D, Frankfurt am Main, Germany.ORCID 0000-0002-1681-8312
Lars KuepferInstitute for Systems Medicine With Focus on Organ Interaction, University Hospital RWTH Aachen, Aachen, Germany.ORCID 0000-0002-8741-7786
Jörg LippertModel-Informed Drug Development, Research & Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.ORCID 0000-0002-0683-2874
Julia MacenteDrug Delivery and Disposition, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.ORCID 0000-0002-4452-5867
Juri SolodenkoModel-Informed Drug Development, Research & Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.ORCID 0000-0001-6922-588X
Alexander StaabClinical Pharmacology, Boehringer Ingelheim Pharma GmbH & co. KG, Ingelheim am Rhein, Germany.
Paul VrenkenNational and Kapodistrian University of Athens, Department of Pharmacy, Zografou, Greece.ORCID 0009-0007-2543-201X
Thomas WendlModel-Informed Drug Development, Research & Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.ORCID 0000-0002-1153-7167
Wilhelmus E A de WitteESQlabs GmbH, Saterland, Germany.
Donato TeutonicoTranslational Medicine & Early Development, Sanofi R&D, Vitry-sur-Seine, France.ORCID 0000-0003-4931-410X
Funding
Physiologically-Based Pharmacokinetic (PBPK) Modeling of Asthma Drugs during PregnancyK23HD112591 · NICHD · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Kathleen Marie Job · 2024 to 2026
$501k
NICHD NIH HHS K23 HD112591
6 · The paper itself
Abstract
In 2017, the free and open-source software Open Systems Pharmacology (OSP) was launched. Since then, OSP has evolved from a small community into a diverse network of stakeholders committed to advancing open-source solutions for model-informed drug development (MIDD). In this context, the first OSP Community Conference was hosted by Novartis in Basel, Switzerland, on October 7-8, 2024, which gathered over 100 attendees from more than 40 institutions. This perspective synthesizes key insights from the conference.
Indexed as
Drug DevelopmentPharmacologySoftwareCongresses as TopicHumansSwitzerlandSystems Biology
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Harnessing Open-Source Solutions: Insights From the First Open Systems Pharmacology (OSP) Community Conference. · full record | Socratic